155 related articles for article (PubMed ID: 35587340)
1. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
3. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
5. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
[TBL] [Abstract][Full Text] [Related]
6. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
7. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
8. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
9. Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis.
Baboudjian M; Gondran-Tellier B; Dariane C; Fiard G; Fromont G; Rouprêt M; Ploussard G
JAMA Oncol; 2023 Jun; 9(6):847-850. PubMed ID: 37079318
[TBL] [Abstract][Full Text] [Related]
10. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Murtola TJ; Kujala PM; Tammela TL
Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
12. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
13. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
14. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
15. 5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care.
Vaselkiv JB; Ceraolo C; Wilson KM; Pernar CH; Rencsok EM; Stopsack KH; Grob ST; Plym A; Giovannucci EL; Olumi AF; Kibel AS; Preston MA; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1460-1465. PubMed ID: 35255119
[TBL] [Abstract][Full Text] [Related]
16. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
17. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
18. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
19. Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6 years follow-up.
Ashrafi AN; Shin T; Marien A; Clifford T; Shoji S; Iwata T; Iwata A; Oishi M; Chopra S; Cai J; Ukimura O; Bahn D; Gill IS; Abreu AL
World J Urol; 2021 Sep; 39(9):3295-3307. PubMed ID: 33683411
[TBL] [Abstract][Full Text] [Related]
20. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.
Robinson D; Garmo H; Bill-Axelson A; Mucci L; Holmberg L; Stattin P
BMJ; 2013 Jun; 346():f3406. PubMed ID: 23778271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
